Similarly, studies focusing on alterations of the gut microbiome in melanoma patients have documented variation in the melanoma treatment response to programed cell death protein 1 (PD-1) checkpoint inhibitors [14,15]. The gene discussed is PDCD1; the disease is melanoma.